Skip to Content
Merck
  • Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.

Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.

British journal of pharmacology (2014-06-26)
N Snelder, B A Ploeger, O Luttringer, D F Rigel, F Fu, M Beil, D R Stanski, M Danhof
ABSTRACT

Previously, a systems pharmacology model was developed characterizing drug effects on the interrelationship between mean arterial pressure (MAP), cardiac output (CO) and total peripheral resistance (TPR). The present investigation aims to (i) extend the previously developed model by parsing CO into heart rate (HR) and stroke volume (SV) and (ii) evaluate if the mechanism of action (MoA) of new compounds can be elucidated using only HR and MAP measurements. Cardiovascular effects of eight drugs with diverse MoAs (amiloride, amlodipine, atropine, enalapril, fasudil, hydrochlorothiazide, prazosin and propranolol) were characterized in spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats following single administrations of a range of doses. Rats were instrumented with ascending aortic flow probes and aortic catheters/radiotransmitters for continuous recording of MAP, HR and CO throughout the experiments. Data were analysed in conjunction with independent information on the time course of the drug concentration following a mechanism-based pharmacokinetic-pharmacodynamic modelling approach. The extended model, which quantified changes in TPR, HR and SV with negative feedback through MAP, adequately described the cardiovascular effects of the drugs while accounting for circadian variations and handling effects. A systems pharmacology model characterizing the interrelationship between MAP, CO, HR, SV and TPR was obtained in hypertensive and normotensive rats. This extended model can quantify dynamic changes in the CVS and elucidate the MoA for novel compounds, with one site of action, using only HR and MAP measurements. Whether the model can be applied for compounds with a more complex MoA remains to be established.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Amlodipine besylate, ≥98% (HPLC)
Supelco
Amlodipine besylate, Pharmaceutical Secondary Standard; Certified Reference Material
Amlodipine for peak identification, European Pharmacopoeia (EP) Reference Standard
Amlodipine besylate, European Pharmacopoeia (EP) Reference Standard
USP
Amlodipine besylate, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Atropine sulfate salt monohydrate, ≥97% (TLC), crystalline
USP
Atropine sulfate, United States Pharmacopeia (USP) Reference Standard
USP
Enalapril maleate, United States Pharmacopeia (USP) Reference Standard
Enalapril maleate, European Pharmacopoeia (EP) Reference Standard
Supelco
Atropine Sulfate, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Enalapril Maleate, Pharmaceutical Secondary Standard; Certified Reference Material